Although the nuclear factor-kappa B (NF-κB) pathway has previously been extensively involved in the development and progression of cancer, recent reviews have highlighted the potential of the NF-κB pathway as a therapeutic target for AD [90, 91]. Here, NFKB1 is linked to Alzheimer disease.